Gubra A/S Logo

Gubra A/S

CRO & biotech accelerating peptide drug discovery for metabolic and fibrotic diseases.

GUBRA | CO

Overview

Corporate Details

ISIN(s):
DK0062266474
LEI:
254900T17RRFZONO6W53
Country:
Denmark
Address:
Hørsholm Kongevej 11 B, 2970 Hørsholm
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Gubra A/S is a specialized preclinical Contract Research Organization (CRO) and biotechnology company focused on peptide-based drug discovery for metabolic and fibrotic diseases, such as obesity, diabetes, and MASH. Founded in 2008, the company operates through two primary business areas: CRO Services, providing advanced preclinical research to accelerate partners' drug development, and Discovery & Partnerships, which develops its own pipeline of next-generation peptide therapeutics. Gubra leverages its expertise in in vivo pharmacology and peptide chemistry to streamline and advance early-stage drug development for its clients and internal projects.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Gubra A/S filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Gubra A/S

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Gubra A/S via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

WOOJUNG BIO, Inc. Logo
Integrated R&D platform offering CRO services, lab construction, and biotech incubation.
South Korea
215380
WPP PLC Logo
Global leader in advertising and marketing, providing AI-powered solutions for top brands.
United Kingdom
WPP
Xenetic Biosciences, Inc. Logo
Advancing DNase & CAR T immune-oncology platforms to treat hard-to-treat cancers.
United States of America
XBIO
Xilio Therapeutics, Inc. Logo
Engineering tumor-activated biologics for cancer to maximize efficacy and minimize toxicity.
United States of America
XLO
XLMEDIA PLC Logo
A former performance marketing company for the sports and gaming industries.
Jersey
XLM
XORTX Therapeutics Inc. Logo
Developing late-stage, uric acid-lowering therapies for gout and progressive kidney disease.
United States of America
XRTX
Xplus Inc. Logo
IT consultancy guiding digital transformation via enterprise architecture & program management.
South Korea
373200
XTL Biopharmaceuticals Ltd. Logo
Acquires and develops late-stage drugs for unmet medical needs, focusing on autoimmune diseases.
Israel
XTLB
YAMADA Consulting Group  CO.,LTD. Logo
Japanese consulting firm offering global M&A, strategy, and financial advisory services.
Japan
4792
Y-Biologics, Inc Logo
Develops novel antibody cancer therapies using proprietary T-cell engager & antibody library tech.
South Korea
338840

Talk to a Data Expert

Have a question? We'll get back to you promptly.